<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03653533</url>
  </required_header>
  <id_info>
    <org_study_id>2017-A01988-45</org_study_id>
    <nct_id>NCT03653533</nct_id>
  </id_info>
  <brief_title>Evaluation of the Function &quot;Stop Before Hypoglycemia&quot; on External Insulin Pump</brief_title>
  <acronym>AAHPI</acronym>
  <official_title>Evaluation of the Function &quot;Stop Before Hypoglycemia&quot; on External Insulin Pump Coupled With the Continuous Measurement of Interstitial Glycemia in Type 1 Diabetic Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ARAIR Assistance</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ARAIR Assistance</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study compares the apparition of hypoglycaemia in type I diabetic patients between 2
      phases: the one without the use of SmartGuard® function and the one with the use of
      SmartGuard® function.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to compare SmartGuard® function with captor and insulin pump to
      improve the glycemia stability in real condition.

      There are several phases:

        -  phase 1: insulin pump without captor (12 weeks)

        -  phase 2: insulin pump with captor and without SmartGuard® function (4X6 days; 4 weeks)

        -  phase 3: insulin pump with captor and with SmartGuard® function (6X6 days; 6 weeks)

        -  phase 4: insulin pump without captor (4 weeks)
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Difficulties for recruitment
  </why_stopped>
  <start_date type="Actual">January 7, 2019</start_date>
  <completion_date type="Actual">October 18, 2019</completion_date>
  <primary_completion_date type="Actual">October 18, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of hypoglycemia between a phase with no SmartGuard® function and a phase with SmartGuard® function</measure>
    <time_frame>6 days</time_frame>
    <description>The primary outcome is the area between the glycemic curve and the hypoglycemic level (70 mg/dL), measured between the 6 last days of the phase without SmartGuard® function and the 6 last days with the use of SmartGuard® function</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Type I Diabetes</condition>
  <arm_group>
    <arm_group_label>MiniMed™ 640G alone</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>MiniMed™ 640G (insulin pump) is used without Captor CGM Enlite® (captor) at phase 1 and phase 4 of the study. ADDQoL, BIPQ and HADS questionnaire are performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MiniMed™ 640G + Captor CGM Enlite®</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>insulin pump coupled with captor without SmartGuard® function tat phase 2 of the study. ADDQoL, BIPQ and HADS questionnaire are performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MiniMed™ 640G + Captor + SmartGuard®</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>insulin pump + captor + SmartGuard® function are used at phase 3 of the study. ADDQoL, BIPQ and HADS questionnaire are performed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MiniMed™ 640G</intervention_name>
    <description>The MiniMed™ 640G corresponds to the medical device = pump using for the delivery of insulin</description>
    <arm_group_label>MiniMed™ 640G + Captor + SmartGuard®</arm_group_label>
    <arm_group_label>MiniMed™ 640G + Captor CGM Enlite®</arm_group_label>
    <arm_group_label>MiniMed™ 640G alone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Captor CGM Enlite®</intervention_name>
    <description>The Captor CGM Enlite® corresponds to the device added for the measurement of the glycemic level</description>
    <arm_group_label>MiniMed™ 640G + Captor + SmartGuard®</arm_group_label>
    <arm_group_label>MiniMed™ 640G + Captor CGM Enlite®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SmartGuard®</intervention_name>
    <description>This SmartGuard® function is used to improve the glycemia stability in real condition</description>
    <arm_group_label>MiniMed™ 640G + Captor + SmartGuard®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  type I diabetic patients undr basal/prandial diet

          -  treated by insuline

          -  with no insuline pump during at least 3 months

          -  with HbA1C dosed during the 3 months before inclusion

        Exclusion Criteria:

          -  minor patients

          -  pregnant woman

          -  already participating to another studies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Pole Sante Sud Le Mans</name>
      <address>
        <city>Le Mans</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 12, 2018</study_first_submitted>
  <study_first_submitted_qc>August 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2018</study_first_posted>
  <last_update_submitted>July 9, 2020</last_update_submitted>
  <last_update_submitted_qc>July 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypoglycemia</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

